STOCK TITAN

Medicus Pharma Regains Compliance with Nasdaq Minimum Equity Requirement for Continued Listing

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Medicus Pharma (MDCX) regained conditional compliance with Nasdaq’s minimum shareholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq notified Medicus on November 18, 2026, that it again met the $2.5 million minimum shareholders’ equity requirement. The determination followed approximately $4.25 million in completed equity financings and the exchange of $10.5 million in Streeterville Capital debt for non-convertible preferred shares.

The financings included a $3.0 million registered direct offering and approximately $1.25 million in insider-led private placements. CEO Raza Bokhari invested $750,000 through an entity he controls. Medicus could face delisting unless it shows continued compliance in its next periodic report, for the period ending December 31, 2026. Other Nasdaq listing requirements still apply.

Loading...
Loading translation...
4 points · 2 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointCompleted equity financings raised approximately $4.25 million: a $3.0 million registered direct offering and approximately $1.25 million in insider-led private placements. 1.6× market cap
  • Major pointDebt exchange removed $10.5 million in Streeterville Capital debt in return for non-convertible preferred shares. 3.9× market cap
  • Moderate pointNasdaq equity compliance was restored conditionally under the $2.5 million minimum for continued listing.
  • Minor pointCEO Raza Bokhari invested $750,000 in the private placements through an entity he controls.

Negative

  • Major pointNew equity issued through the registered direct offering and insider-led private placements diluted existing shareholders.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Delisting remains possible unless Medicus demonstrates continued equity compliance in its report for the period ending December 31, 2026.

News Explained

Medicus has regained conditional Nasdaq compliance; if it does not evidence the $2.5 million equity minimum in its next periodic report for the period ending December 31, 2026, Nasdaq would provide written notice of a delisting determination, which the company could appeal to a Nasdaq Hearings Panel.

Key Figures

Minimum shareholders’ equity: $2.5 million Equity financings: Approximately $4.25 million Registered direct offering: $3.0 million +4 more
Minimum shareholders’ equity
$2.5 million
Nasdaq continued-listing requirement
Equity financings
Approximately $4.25 million
Completed financings cited as the basis for regained compliance
Registered direct offering
$3.0 million
Component of the completed equity financings
Private placements
Approximately $1.25 million
Component of the completed equity financings
CEO investment
$750,000
Investment through a controlled entity
Debt exchanged
$10.5 million
Exchanged for non-convertible preferred shares
Next compliance report
December 31, 2026
Compliance is conditioned on evidencing continued equity compliance in the report for this period

Historical Context

1 past event · Latest: Nov 16
1 event
  1. Nov 16

    Equity financing

    24h Move
    -13.3%

    Closed $4.25 million equity financings and exchanged $10.5 million debt, pending Nasdaq confirmation.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

form 8-k, non-convertible preferred shares, antibody-drug conjugate, gnrh antagonist
4 terms
form 8-k regulatory
"Current Report on Form 8-K filed with the Securities and Exchange Commission"
A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.
non-convertible preferred shares financial
"exchanged $10.5 million of indebtedness held by Streeterville Capital, LLC for non-convertible preferred shares"
Preferred shares that do not carry any option to convert into common stock; they provide holders with specified dividend rights and priority over common shareholders for dividend payments and liquidation proceeds but remain equity without becoming common shares. They often have fixed or stated dividends, may include features like cumulative dividends or call provisions, and typically offer limited or no voting rights compared with common stock.
antibody-drug conjugate medical
"an investigational antibody-drug conjugate molecule utilizing Pfizer’s established vedotin linker-payload platform"
An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.
gnrh antagonist medical
"an investigational next-generation GnRH antagonist"
A GnRH antagonist is a type of medicine that blocks the body’s chemical switch that tells the ovaries or testes to make sex hormones like estrogen or testosterone. Like turning off a faucet that controls hormone flow, this immediate block lowers hormone levels and is used in conditions such as hormone-driven cancers and fertility treatments. Investors follow GnRH antagonists for their potential market size, regulatory approvals, and how they fit into a drug maker’s pipeline and revenue outlook.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Nasdaq Confirmation follows CEO-Led $4.25 million in Equity Financings and $10.5 million debt exchange to satisfy the alternative minimum shareholders’ equity standard

PHILADELPHIA, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision-guided, biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that it has received written notification on November 18, 2026 (the “Conditional Compliance Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million in shareholders’ equity for continued listing on The Nasdaq Capital Market.

Nasdaq based its determination on the transactions described in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on November 16, 2026. Additional details may be found in the Company’s Current Report on Form 8-K filed with the SEC today.

As previously disclosed, the Company completed approximately $4.25 million in equity financings, comprising a $3.0 million registered direct offering and approximately $1.25 million in private placements led by Company insiders, including a $750,000 investment by Dr. Raza Bokhari through a controlled entity. The Company also exchanged $10.5 million of indebtedness held by Streeterville Capital, LLC for non-convertible preferred shares.

“Nasdaq’s confirmation recognizes the progress we have made in strengthening Medicus’ balance sheet,” stated Dr. Raza Bokhari, Medicus’ Executive Chairman and CEO. “My most recent investment alongside other directors and officers reflects our commitment to the Company. We remain focused on disciplined capital allocation and advancing CD228V as the lead program in our precision oncology portfolio.”

Under the Conditional Compliance Notice, the Company’s compliance is conditioned upon the Company evidencing continued compliance with the minimum shareholders’ equity requirement in its next periodic report for the period ending December 31, 2026. If the Company does not evidence compliance in that report, it may be subject to delisting. Nasdaq would provide written notification of any such determination, which the Company could appeal to a Nasdaq Hearings Panel.

The Company remains subject to Nasdaq’s other continued listing requirements, and there can be no assurance that it will maintain compliance with the minimum shareholders’ equity requirement or other continued listing requirements in the future.

For further information contact:

Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com  

Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicuspharma.com

About Medicus Pharma Ltd.

Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision-guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets. The Company is actively engaged in multiple countries across three continents.

The Company’s current therapeutic assets are:

CD228V ADC, an investigational antibody-drug conjugate molecule utilizing Pfizer’s established vedotin linker-payload platform, directed against melanotransferrin (CD228), a cell-surface protein expressed across multiple solid tumor types, such as melanoma, squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and esophageal cancer.

SkinJect®, an investigational novel localized immuno-oncology precision product focused on basal cell carcinoma (BCC) lesions in Gorlin Syndrome patients, a rare autosomal dominant disease also called nevoid BCC syndrome.

Teverelix®, an investigational next-generation GnRH antagonist, is being developed as a first-in-market product for cardiovascular high-risk advanced prostate cancer patients, patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate and symptomatic endometriosis.

Medicus’ strategy is to advance select programs through Phase 2 proof-of-concept and key clinical and regulatory inflection points that substantially reduce development risk and increase their attractiveness to potential pharmaceutical partners. By generating decision-grade clinical, regulatory and operational datasets, the Company seeks to create opportunities for strategic collaborations, regional licensing transactions and broader commercialization partnerships with established pharmaceutical companies. As data matures across its programs, Medicus intends to continue building differentiated development packages designed to maximize asset value while maintaining capital efficiency and development focus.

Cautionary Notice on Forward-Looking Statements

Certain information in this news release constitutes “forward-looking statements” or “forward-looking information” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws (collectively, “forward-looking statements”). “Forward-looking statements” are defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the continued listing of the Company’s securities on Nasdaq, the Company’s ability to maintain compliance with the minimum shareholders’ equity requirement and Nasdaq’s other continued listing requirements, and whether Nasdaq will determine that the Company has satisfied the condition set forth in the Conditional Compliance Notice. Forward-looking statements are often, but not always, identified by the use of such terms as "may", “on track”, “aim”, "might", "will", "will likely result", “could,” “designed,” "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target", “goal”, “strive”, “prioritize”, “pursue”, “intended”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2025, as amended, and its quarterly report on Form 10-Q for the quarter ended September 30, 2026, and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What must Medicus Pharma (MDCX) do to keep its Nasdaq equity compliance?

Medicus must show at least $2.5 million in shareholders’ equity in its next periodic report, covering the period ending December 31, 2026. It remains subject to Nasdaq’s other continued listing requirements.

Can Medicus Pharma (MDCX) appeal if Nasdaq decides to delist it over shareholders’ equity?

Medicus could appeal to a Nasdaq Hearings Panel if Nasdaq determines that the company should be delisted. Nasdaq would notify Medicus of that determination in writing.

Keep reading